article thumbnail

J&J copay lawsuit against drug benefit firm gets green light

pharmaphorum

While SaveOnSP is the nominal target of the lawsuit, it claims to expose one of the failings in the US health insurance sector, adding fire to an increasingly heated exchange between pharma manufacturers and pharmacy benefit managers (PBMs), which have blamed each other for high medicine prices in the US.

article thumbnail

Five for Friday March 8: Celebrating Success in Advancing Medication Use Quality

PQA

Ensuring the quality of medication use is critically important for rare disease patients, payers, clinicians, specialty pharmacies and everyone with a role in the care process. February 29 was Rare Disease Day, providing an opportunity to raise awareness of the impact of rare diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before generic versions reached the market. In 2020, it also paid $345 million to resolve a series of cases brought by the federal government under the Foreign Corrupt Practices Act (FCPA).

article thumbnail

Participate in the Measure Development Process in 2023

PQA

The Specialty Pharmacy Abandonment Rate TEP will define a measure around primary abandonment rate of specialty pharmacy prescriptions. The Health Equity TEP will review how PQA measures can be a tool to foster health equity by producing recommendations related to stratification for quality measures.

article thumbnail

Five for Friday September 22: Celebrating Success in Advancing Medication Use Quality

PQA

We continue to play a central role in driving meaningful improvements and positive changes related to medication safety, adherence and appropriate use.The 2023 PQA Annual Report documents our progress towards Blueprint PQA 2025. The data can also show short term results.

article thumbnail

In the Face of Resistance, 340B Coalition Summer Conference Proves Program’s Worth

Omnicell

Jangus Whitner, Director of Pharmacy Services at PrimaryOne Health also shared the results of a qualitative research study that documented direct patient experiences using the 340B program on injectable diabetes medications. Omnicell can be a valued partner in this effort.